These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21443749)

  • 41. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis.
    Chaouchi N; Wallon C; Goujard C; Tertian G; Rudent A; Caput D; Ferrera P; Minty A; Vazquez A; Delfraissy JF
    Blood; 1996 Feb; 87(3):1022-9. PubMed ID: 8562926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation and high frequency expression of autoantibody-associated cross-reactive idiotypes linked to the VHI subgroup in CD5-expressing B lymphocytes from patients with chronic lymphocytic leukaemia (B-CLL).
    Shokri F; Mageed RA; Richardson P; Jefferis R
    Scand J Immunol; 1993 Jun; 37(6):673-9. PubMed ID: 7686301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
    Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
    Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells.
    Jurlander J; Lai CF; Tan J; Chou CC; Geisler CH; Schriber J; Blumenson LE; Narula SK; Baumann H; Caligiuri MA
    Blood; 1997 Jun; 89(11):4146-52. PubMed ID: 9166857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD.
    Zupo S; Massara R; Dono M; Rossi E; Malavasi F; Cosulich ME; Ferrarini M
    Blood; 2000 Feb; 95(4):1199-206. PubMed ID: 10666191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Signaling capacity of FcgammaRII isoforms in B-CLL cells.
    Gamberale R; Fernández-Calotti P; Sanjurjo J; Arrossagaray G; Avalos JS; Geffner J; Giordano M
    Leuk Res; 2005 Nov; 29(11):1277-84. PubMed ID: 15908001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals.
    Schuler M; Tretter T; Schneller F; Huber C; Peschel C
    Immunobiology; 1999 Feb; 200(1):128-39. PubMed ID: 10084701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti-CD40 antibody.
    Katada Y; Tanaka T; Ochi H; Aitani M; Yokota A; Kikutani H; Suemura M; Kishimoto T
    Eur J Immunol; 1996 Jan; 26(1):192-200. PubMed ID: 8566066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.
    Deaglio S; Capobianco A; Bergui L; Dürig J; Morabito F; Dührsen U; Malavasi F
    Blood; 2003 Sep; 102(6):2146-55. PubMed ID: 12763926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC.
    Perez-Chacon G; Vargas JA; Jorda J; Morado M; Rosado S; Martin-Donaire T; Losada-Fernandez I; Rebolleda N; Perez-Aciego P
    Leuk Res; 2007 Feb; 31(2):183-93. PubMed ID: 16725198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory coreceptors activated by antigens but not by anti-Ig heavy chain antibodies install requirement of costimulation through CD40 for survival and proliferation of B cells.
    Hokazono Y; Adachi T; Wabl M; Tada N; Amagasa T; Tsubata T
    J Immunol; 2003 Aug; 171(4):1835-43. PubMed ID: 12902484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
    Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
    Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
    Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
    Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.
    Barragán M; Bellosillo B; Campàs C; Colomer D; Pons G; Gil J
    Blood; 2002 Apr; 99(8):2969-76. PubMed ID: 11929788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.
    Damle RN; Calissano C; Chiorazzi N
    Best Pract Res Clin Haematol; 2010 Mar; 23(1):33-45. PubMed ID: 20620969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
    Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N
    Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.
    Danilov AV; Danilova OV; Brown JR; Rabinowitz A; Klein AK; Huber BT
    Exp Hematol; 2010 Dec; 38(12):1167-77. PubMed ID: 20817072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.